Patent Foramen Ovale

Publication Date: April 29, 2020

Key Points

Key Points

  • For patients with cryptogenic stroke and PFO, percutaneous PFO closure probably reduces the risk of stroke recurrence (HR-0.41, summary rate difference -0.67% per year), probably is associated with a periprocedural complication rate of 3.9%, and probably is associated with the development of serious non-periprocedural atrial fibrillation (RR-2.72, summary rate difference 0.33% per year).
  • For patients with cryptogenic stroke and PFO, anticoagulation medication and antiplatelet medication are possibly equally effective at reducing recurrent stroke.

Management

...Management...

...Recom...

...atients being considered for PFO closure, clin...

...atients being considered for PFO closure, clinicia...

...ients being considered for PFO closure, clinic...

...s being considered for PFO closure, clinician...

...elect patients being considered for P...

...ing considered for PFO closure, clinic...

...n patients being considered for PFO closure,...

...atients being considered for PFO closure,...

...ing PFO closure, patients should be assessed...

...her risk alternative mechanism of stroke is i...

...efore undergoing PFO closure, patients should...

...atients with a PFO detected after stroke and...

...younger than 60 years with a PFO and...

...linicians may inform patients that...

...FO closure may be offered in other populations,...

...osure may be offered to younger patien...

...t for whom PFO closure is being considere...


...Recommendations Rega...

...opt to receive medical therapy alone wi...

...ients who would otherwise be considered good c...


...gure 1. Management Algori...